Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the clinical characteristics and hemodynamic
profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic
sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects
with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma